Commercial Daiichi Sankyo shares slip after delaying annual earnings report BioSpaceDaiichi Sankyo's full-year report was originally scheduled for April 27 but has now been pushed back to May 11.CommercialRead full story pharminent April 24, 2026 (Last updated: April 24, 2026) BioSpace Daiichi Sankyo’s full-year report was originally scheduled for April 27 but has now been pushed back to May 11. CommercialRead full story Post navigation Previous: Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancerNext: Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings Related Stories Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026 Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026
